EN

What the GLP‑1 trials found

Pick a medicine and dose to see its main trial as the Health Canada product monograph reports it: average weight change, how many people reached each amount, and the side effects and stopping rates beside them.

Nothing you enter leaves your device Every number cites its monograph section
Trial averages, not a prediction for you. This doesn't replace the monograph or your prescriber. Some people lose much more than the average and some lose very little. Talk to your doctor, nurse practitioner or pharmacist before starting, stopping or changing a medicine.Information only, not a promotion. Every medicine named here is prescription-only. Only a doctor can decide whether one is right for you and prescribe it. We don't recommend, rank or favour any medicine. Where we list several, they're in alphabetical order. We don't sell medicines or take money from drug companies.

Pick a medicine and dose

Medicine
kg

Shows what the trial's averages and proportions would mean in kilograms (with pounds). Not a prediction.

How these trials work
  • People were put into groups by chance: one got the medicine, one got a placebo (a dummy injection or dummy pill with no medicine in it).
  • Both groups got the same diet and activity advice.
  • The gap between the two groups is what the medicine added.
These trials can't be ranked against each other. They had different people, lengths, doses and diet advice, and ran at different times. The monographs themselves say side-effect rates "should not be compared to the rates in the clinical trials of another drug". Only a head-to-head trial tests two medicines in the same trial: see Compare.

Private by design: worked out in your browser. Nothing is sent or stored, and nothing goes in the link. Privacy notice

How this works

For each medicine we use the main placebo-controlled trial in its Health Canada product monograph (the official prescribing information), section 14 ("Clinical Trials"). Side effects and stopping rates come from section 8 ("Adverse Reactions"), which often pools several trials; the card says which. Trial names and who paid for each trial come from the published paper or its ClinicalTrials.gov record. Every number sits in one data block on this page with its source.

"Mean" weight change is the average for the whole group. The share who reached at least 5% (and 10, 15 or 20%, where the monograph gives it) shows the spread: it's a range, not one number. If you enter your weight, we multiply it by the same percentages. That's arithmetic on trial averages, not a forecast. Where the Canadian monograph doesn't give a number, we leave it out.

Ozempic, Mounjaro and Rybelsus are approved in Canada for type 2 diabetes, not weight management. Their monographs report weight change from diabetes trials in kilograms only, so we show that and nothing more. For Ozempic, the monograph's side-effect table compares it with a mixed group that got either placebo or another diabetes medicine, and the card says so.

What this can't tell you

  • How much you will lose. Your result depends on you, your dose and how long you take it, and isn't predicted by a trial average.
  • Which medicine works more. Separate trials can't be ranked.
  • What happens after stopping. Weight usually comes back in part: see Stopping and the long term.
  • Rare or long-term risks. Those are in each monograph's warnings, and in Side effects and risks.
  • Results for generic semaglutide. Generics are approved as copies of Ozempic and have no weight trials of their own, so they aren't listed.

Questions people ask

Can I compare the numbers for different medicines?

No. Each trial had different people, lengths, doses and diet advice, so the numbers can't be ranked against each other. Only a head-to-head trial, where both medicines are tested in the same trial, can compare them.

Is this how much weight I will lose?

No. These are trial averages, not a prediction for you. In every trial some people lost much more than the average and some lost very little. That's why the tool shows how many people reached each amount, not one number.

What is a placebo?

A dummy injection or dummy pill with no medicine in it. In these trials people were put into groups by chance, and both groups got the same diet and activity advice. The gap between the medicine group and the dummy group is what the medicine added.

Why are Ozempic, Mounjaro and Rybelsus shown differently?

In Canada they're approved for type 2 diabetes, not weight management. Their monographs report weight change from diabetes trials in kilograms, and not how many people lost 5% or more, so the tool shows only the average change for them.

Is anything I enter saved or sent?

No. The weight you enter is used only in your browser to turn the trial percentages into kilograms. Nothing is sent or stored.

Sources

  1. Novo Nordisk Canada. Wegovy (semaglutide injection) product monograph, 2 October 2026. Section 14.1 (Table 9: STEP 1) and 8 (8.1 stopping rate; 8.2 Table 4, STEP 1 to 3 pooled). Product monograph (PDF) · Drug Product Database. Checked 14 Oct 2026.
  2. Eli Lilly Canada. Zepbound (tirzepatide injection) product monograph, 11 June 2026. Section 14.1 (Table 7: SURMOUNT-1) and 8.2 (stopping rates and Table 2, SURMOUNT-1 and -2 pooled). Product monograph (PDF) · Drug Product Database. Checked 14 Oct 2026.
  3. Novo Nordisk Canada. Saxenda (liraglutide injection) product monograph, 10 September 2025. Section 14 (Table 7: Study 1) and 8 (8.1 stopping rate; 8.2 Table 3, 5 adult trials pooled). Product monograph (PDF) · Drug Product Database. Checked 14 Oct 2026.
  4. Novo Nordisk Canada. Ozempic (semaglutide injection) product monograph, 13 July 2026. Section 14.1 (Table 10: SUSTAIN 5, with basal insulin) and 8.2 (Table 2 and gastrointestinal text, 7 trials pooled against placebo or another diabetes medicine). Product monograph (PDF) · Drug Product Database. Checked 14 Oct 2026.
  5. Eli Lilly Canada. Mounjaro (tirzepatide injection) product monograph, 23 June 2026. Section 14.1 (Table 9: SURPASS-1) and 8.2 (Table 2 and gastrointestinal text, 2 placebo-controlled trials pooled). Product monograph (PDF) · Drug Product Database. Checked 14 Oct 2026.
  6. Novo Nordisk Canada. Rybelsus (semaglutide tablets) product monograph, 13 July 2026. Section 14.1 (Table 9: PIONEER 1), 4.2 (Table 1, equivalent tablets) and 8.2 (Table 3, discontinuation and gastrointestinal text, PIONEER 1 and 8 pooled). Product monograph (PDF) · Drug Product Database. Checked 14 Oct 2026.
  7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. PMID 33567185. Funded by Novo Nordisk. PubMed. Checked 14 Oct 2026.
  8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. PMID 35658024. Supported by Eli Lilly. PubMed. Checked 14 Oct 2026.
  9. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). N Engl J Med 2015;373:11-22. PMID 26132939. Funded by Novo Nordisk. PubMed. Checked 14 Oct 2026.
  10. ClinicalTrials.gov NCT02305381 (SUSTAIN 5): semaglutide once weekly versus placebo as add-on to basal insulin; lead sponsor Novo Nordisk A/S. Paper: Rodbard HW et al. J Clin Endocrinol Metab 2018;103:2291-2301, PMID 29688502. ClinicalTrials.gov. Checked 14 Oct 2026.
  11. ClinicalTrials.gov NCT03954834 (SURPASS-1): tirzepatide in type 2 diabetes not controlled with diet and exercise alone; lead sponsor Eli Lilly and Company. Paper: Rosenstock J et al. Lancet 2021;398:143-155, PMID 34186022. ClinicalTrials.gov. Checked 14 Oct 2026.
  12. ClinicalTrials.gov NCT02906930 (PIONEER 1): oral semaglutide versus placebo in type 2 diabetes treated with diet and exercise only; lead sponsor Novo Nordisk A/S. Paper: Aroda VR et al. Diabetes Care 2019;42:1724-1732, PMID 31186300. ClinicalTrials.gov. Checked 14 Oct 2026.

Last checked 14 Oct 2026 · Next review due 14 Jan 2027

How this tool was made. Written by the GLP Guidebook team from the Health Canada product monographs and the trial records above, each opened and checked. The trials were paid for by the makers of the medicines (Novo Nordisk or Eli Lilly). We don't recommend any brand, company or seller, and we earn nothing from them. It's general information, not medical advice, and it doesn't replace the monograph or your prescriber. Talk to your doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. In an emergency, call 9-1-1. How we write